Skip to main content
Skip to main content
LNDZF logo

Evome Medical Technologies Inc. (LNDZF) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 $0.00 (0.00%) |CouncilBearish Lean · 24 · F
Vol: 10K| 52-wk range: $0.0001 – $0.006

Beta 2.29: the stock has moved about 129% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Evome Medical Technologies Inc. (LNDZF) trades at $0.0001. Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices for pain management and physical therapy. Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026
Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices for pain management and physical therapy. The company operates in the Americas and internationally, offering a diverse product portfolio including isokinetic dynamometers, gait trainers, and electrical stimulation devices.

Analyst Coverage for LNDZF: LNDZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LNDZF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the LNDZF film Every key number, told as a short cinematic story — just press play. ~2 min

Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Council Score · Weighted Average of 3 Disciplines
Bearish Lean 24/100 · F

LNDZF: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Unfavorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Evome Medical Technologies Inc. (LNDZF) Healthcare & Pipeline Overview

CEOChristopher Heath
Employees195
HeadquartersShirley, US
IPO Year2015

Evome Medical Technologies Inc. focuses on developing and distributing medical devices for pain management and physical therapy across the Americas and internationally. With a diverse product portfolio and a negative P/E ratio, the company operates in a competitive market, emphasizing innovation in rehabilitation technology.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for LNDZF?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Evome Medical Technologies Inc. presents a speculative investment opportunity in the medical device sector. With a negative P/E ratio of -2.20 and a negative profit margin of -23.9%, the company's current profitability is a concern. However, the gross margin of 32.6% indicates potential for improved profitability with better cost management and revenue scaling. The company's beta of 2.29 suggests high volatility relative to the market. Key growth catalysts include expansion into new geographic markets and the introduction of innovative products. The company's success hinges on its ability to navigate regulatory hurdles, secure market adoption of its products, and achieve sustainable profitability.

Based on FMP financials and quantitative analysis

LNDZF Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Gross Margin of 32.6% indicates potential for profitability improvements.

  • Negative P/E ratio of -2.20 reflects current losses.
  • Profit Margin of -23.9% highlights the need for cost optimization.
  • Beta of 2.29 suggests high volatility compared to the market.
  • Market Cap of $0.00B indicates a micro-cap company.

Who Are LNDZF's Competitors?

LNDZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
RDGL Vivos Inc. $0.05 0.00% $23.9M 619-signal
SNWV SANUWAVE Health, Inc. $4.00 -0.99% $34.4M 365-pillar
HYPD Hyperion DeFi, Inc. $3.59 -2.18% $54.4M 365-pillar
LNSR LENSAR, Inc. $8.23 -0.96% $101M 485-pillar
APYX Apyx Medical Corporation $2.89 -5.25% $122M 365-pillar
JMDMF Japan Medical Dynamic Marketing, Inc. $5.00 0.00% $132M 499-signal
INGN Inogen, Inc. $5.18 -1.71% $140M 365-pillar
ELMD Electromed, Inc. $26.65 -1.55% $221M 875-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LNDZF's Key Strengths?

Diverse product portfolio in pain management and rehabilitation.

  • Distribution network in the Americas and internationally.
  • Proprietary technology in rehabilitation devices.
  • Focus on non-invasive treatment options.

What Are LNDZF's Weaknesses?

Negative P/E ratio and profit margin.

  • High beta indicating high volatility.
  • Limited brand recognition compared to larger competitors.
  • Dependence on regulatory approvals for new products.

What Could Drive LNDZF Stock Higher?

Potential FDA approval for new rehabilitation device in Q4 2026.

  • Expansion of distribution network into new geographic markets.
  • Development of wearable technology for remote patient monitoring.
  • Strategic partnerships with rehabilitation centers by Q2 2027.

What Are the Key Risks for LNDZF?

Financial-distress signal — its Altman Z-Score of -3.77 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-44.2%) — the business is not currently generating profit on shareholder capital.
  • Intense competition from established medical device companies.
  • Stringent regulatory requirements and approval processes.
  • Economic downturns affecting healthcare spending.
  • Technological obsolescence and the need for continuous innovation.
  • Negative P/E ratio and profit margin impacting financial stability.

What Are the Growth Opportunities for LNDZF?

  • Expansion into Emerging Markets: Evome Medical Technologies Inc. can pursue growth by expanding its distribution network into emerging markets in Asia-Pacific and Latin America. These regions have a growing demand for advanced medical devices due to increasing healthcare expenditure and rising awareness of rehabilitation therapies. The market size for medical devices in emerging markets is projected to reach $200 billion by 2028, offering a significant opportunity for Evome to increase its revenue and market share. Timeline: 2-3 years.
  • Development of Wearable Technology: Investing in the development of advanced wearable technology for remote patient monitoring and rehabilitation can drive growth. The wearable medical device market is expected to reach $30 billion by 2027, driven by the increasing adoption of telehealth and remote patient monitoring solutions. Evome can leverage its expertise in rehabilitation devices to create innovative wearable solutions that improve patient outcomes and reduce healthcare costs. Timeline: 1-2 years.
  • Strategic Partnerships with Rehabilitation Centers: Forming strategic partnerships with leading rehabilitation centers and hospitals can enhance Evome's market reach and product adoption. These partnerships can provide access to a large patient base and facilitate the integration of Evome's devices into clinical practice. The market for rehabilitation services is growing at a rate of 5-7% annually, driven by the increasing prevalence of musculoskeletal disorders and neurological conditions. Timeline: Ongoing.
  • Focus on Non-Invasive Pain Management Solutions: The increasing demand for non-invasive pain management solutions presents a significant growth opportunity for Evome. Evome can capitalize on this trend by developing and marketing innovative non-invasive devices that provide effective pain relief without the side effects of traditional medications. Timeline: 1-2 years.
  • Leveraging Telehealth Platforms: Integrating Evome's devices with telehealth platforms can expand its reach and improve patient access to rehabilitation services. The telehealth market is experiencing rapid growth, driven by the increasing adoption of remote patient monitoring and virtual consultations. By partnering with telehealth providers, Evome can offer its devices as part of comprehensive telehealth solutions, reaching a wider patient population and generating recurring revenue streams. Timeline: Ongoing.

What Are LNDZF's Competitive Advantages?

  • Proprietary technology in rehabilitation devices.
  • Established distribution network in the Americas.
  • Diverse product portfolio catering to various rehabilitation needs.
  • Strong relationships with healthcare providers and rehabilitation centers.

What Does LNDZF Do?

Evome Medical Technologies Inc. is a medical device company specializing in the development, manufacture, and distribution of products for pain management and physical therapy. Founded with the vision of advancing rehabilitation technology, the company has evolved to offer a comprehensive range of devices designed for the prevention, treatment, and rehabilitation of the human body. Its product portfolio includes isokinetic dynamometers, perturbation gait trainers, balance assessment and recovery devices, neuromuscular electrical and transcutaneous electrical nerve stimulation (TENS) devices, ultrasound treatment devices, and wearable technology. These products are distributed throughout the Americas and internationally, targeting healthcare providers and patients seeking advanced solutions for pain management and physical rehabilitation. Evome Medical Technologies Inc. aims to improve patient outcomes through innovative medical devices and technologies, positioning itself as a key player in the medical device industry.

What Products and Services Does LNDZF Offer?

  • Develops medical devices for pain management.
  • Manufactures physical therapy equipment.
  • Distributes products in the Americas and internationally.
  • Offers isokinetic dynamometers for strength testing.
  • Provides perturbation gait trainers for balance rehabilitation.
  • Supplies neuromuscular electrical stimulation devices.
  • Offers ultrasound treatment devices.
  • Develops wearable technology for patient monitoring.

How Does LNDZF Make Money?

  • Develops and manufactures medical devices.
  • Sells products directly to healthcare providers and rehabilitation centers.
  • Distributes products through a network of distributors in the Americas and internationally.
  • Generates revenue from device sales and service contracts.

What Industry Does LNDZF Operate In?

Evome Medical Technologies Inc. operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory oversight. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Competition is intense, with established players and emerging companies vying for market share. Evome Medical Technologies Inc. focuses on the pain management and physical therapy segments, which are experiencing growth due to the increasing demand for non-invasive treatment options and rehabilitation services. The company's success depends on its ability to differentiate its products, navigate regulatory pathways, and establish strong relationships with healthcare providers.

Who Are LNDZF's Key Customers?

  • Hospitals and rehabilitation centers.
  • Physical therapists and chiropractors.
  • Sports medicine clinics.
  • Individual patients requiring pain management and rehabilitation.
Model self-rating on this text: 79% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low 23/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price is current
  • Latest filing 645 days ago
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 60
2026-08-26 60
2026-08-29 60
2026-09-01 60
2026-09-04 60
2026-09-07 60
2026-09-10 60

What changed?

The score has stayed at 60.

Over the same 18 days the stock moved +0.0%.

Net buying

Insider Activity

The most recent 3 insider filings for Evome Medical Technologies Inc. break down as 0 sales and 3 purchases. On net that is roughly 325K shares acquired (about $388K) — insiders putting money in tends to read as conviction.

F-Score 4/9

Financial Health

Evome Medical Technologies Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.77 places it in the distress zone, a signal of elevated financial risk.

ROE -44%

Key Financial Metrics

Return on equity for Evome Medical Technologies Inc. stands at -44.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.6%, the inverse of the P/E and a quick read on earnings relative to price.

LNDZF Revenue & Earnings Trend

In Q3 FY2024, LNDZF generated $10.0M in top-line revenue, marking a sequential decrease of 5.0%. The company recorded a net loss of $1.1M, with diluted EPS of $-0.01. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely.

Company Profile

Evome Medical Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Shirley, US. The company is led by CEO Christopher Heath. LNDZF has traded publicly since 2015.

LNDZF Financials

Fundamental Snapshot

Return on Equity (TTM)
-44.2%
Current Ratio
0.9

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Diverse product portfolio in pain management and rehabilitation.
  • Distribution network in the Americas and internationally.
  • Proprietary technology in rehabilitation devices.
  • Focus on non-invasive treatment options.

Bear Case

  • Negative P/E ratio and profit margin.
  • High beta indicating high volatility.
  • Limited brand recognition compared to larger competitors.
  • Dependence on regulatory approvals for new products.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 FY2024 C$10M -C$1M -C$0.01
Q2 FY2024 C$11M -C$2M -C$0.03
Q1 FY2024 C$12M -C$4M -C$0.05

Q3 FY2024 · filed 5 Dec 2024 · SEC EDGAR →

Based on FMP financials and quantitative analysis · Reported in CAD

LNDZF Latest News

No recent news available for LNDZF.

LNDZF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LNDZF.

Price Targets

Wall Street price target analysis for LNDZF.

LNDZF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LNDZF; grades run from A+ (80-100) to F (below 30).

Leadership: Christopher Heath

CEO

Christopher Heath serves as the CEO of Evome Medical Technologies Inc. He has extensive experience in the medical device industry, with a background in strategic leadership and business development. Prior to joining Evome, Mr. Heath held various leadership positions at medical technology companies, where he focused on driving growth and innovation. He holds a degree in Business Administration and has completed executive education programs in healthcare management.

Track Record: Since assuming the role of CEO, Christopher Heath has focused on expanding Evome's product portfolio and strengthening its distribution network. He has overseen the launch of several new products and has implemented strategies to improve operational efficiency. Under his leadership, the company has navigated regulatory challenges and has positioned itself for future growth in the competitive medical device market.

LNDZF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Evome Medical Technologies Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk. This tier is often associated with speculative investments and should be approached with caution.

  • OTC Tier: OTC Other
Liquidity: As an OTC stock, LNDZF's liquidity may be limited, resulting in wider bid-ask spreads and potential difficulties in buying or selling large quantities of shares without significantly impacting the price. Investors should be aware of the potential for price volatility and the challenges associated with executing trades in a timely manner. Low trading volumes can exacerbate these issues, making it crucial to carefully consider the potential risks before investing.
OTC Risk Factors:
  • Limited financial disclosure increases information asymmetry.
  • Lower liquidity can lead to price volatility.
  • Fewer regulatory requirements increase the risk of fraud or mismanagement.
  • Higher potential for dilution through stock issuances.
  • OTC Other status may deter institutional investors.
Due Diligence Checklist:
  • Verify the company's financial statements and disclosures.
  • Assess the company's management team and their track record.
  • Research the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and legal standing.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor before investing.
  • Confirm the legitimacy of the company's operations and assets.
Legitimacy Signals:
  • Established product portfolio in pain management and rehabilitation.
  • Distribution network in the Americas and internationally.
  • Experienced management team led by Christopher Heath.
  • Focus on innovative medical device technology.

LNDZF Healthcare Stock FAQ

Is LNDZF a good stock?

Stock Expert AI does not rate LNDZF buy, sell or hold. Evome Medical Technologies Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

How does Evome Medical Technologies Inc. navigate regulatory approval processes?

Evome Medical Technologies Inc. must adhere to stringent regulatory requirements set by agencies such as the FDA in the United States and similar bodies in international markets.

What are the key factors to evaluate for LNDZF?

Evaluate LNDZF on fundamentals, analyst consensus, and risk factors. With a negative P/E ratio of -2.20 and a negative profit margin of -23.9%, the company's current profitability is a concern. Not financial advice.

How frequently does LNDZF data refresh on this page?

LNDZF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven LNDZF's recent stock price performance?

Evome Medical Technologies Inc. (LNDZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in pain management and rehabilitation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LNDZF overvalued or undervalued right now?

Evome Medical Technologies Inc. (LNDZF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of LNDZF?

Yes, most major brokerages offer fractional shares of Evome Medical Technologies Inc. (LNDZF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track LNDZF's earnings and financial reports?

Evome Medical Technologies Inc. (LNDZF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for LNDZF earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is limited to market cap, P/E ratio, profit margin, gross margin, beta, and dividend yield.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover